Aripiprazole augmentation in treatment-resistant depression.
Aripiprazole augmentation in treatment-resistant depression.
复制标题
DOI：
10.1080/10401230490521954
复制
发表时间：
2004-10-01
期刊：
影响因子：
--
通讯作者：
Jamhour, Nowal J
中科院分区：
文献类型：
--
作者：
Barbee, James G;Conrad, Erich J;Jamhour, Nowal J
背景技术背景：证据正在积累，以支持使用非典型抗精神病药作为顽固性心境障碍的连续治疗，虽然目前还没有发表的数据，一个非典型抗精神病药在难治性抑郁症的疗效时，以前的试验从同一类药物已经失败。作者假设，阿立哌唑将有效地增加抗抑郁药治疗的非精神病性单相抑郁症的耐药患者谁以前失败的另一种非典型的精神抑制剂的试验。这项研究是一项回顾性图表审查的疗效阿立哌唑加强在30个治疗，既往多次抗抑郁药试验失败且至少一种非典型抗精神病药强化治疗失败的难治性单相抑郁患者。前瞻性的功能和临床的全球印象，改善分数的全球评估完成对每个病人在整个treatment.RESULTS：利用意向治疗分析（包括9例谁退出前完成6周），46.7%（14/30）的患者被评为大大改善或非常改善与治疗。这种改善与治疗抗性的Thase-Rush分期呈负相关。GAF评分也有显著改善。最初改善随后复发的14例患者中有6例（产生26.7%的长期净反应率）。结论：阿立哌唑可能是有效的抗抑郁增强剂在高度治疗耐药的患者谁失败了以前的另一个非典型的抗精神病药物的试验。
BACKGROUND: Evidence is accumulating to support the use of atypical neuroleptics as adjunctive treatment for refractory mood disorders, although there are currently no published data on the efficacy of an atypical neuroleptic in treatment-resistant depression when a previous trial of drug from the same class has failed. The authors hypothesized that aripiprazole would be efficacious in augmenting antidepressant treatment in resistant patients with non-psychotic unipolar depression who had previously failed a trial of another atypical neuroleptic.METHODS: This study was a retrospective chart review of the efficacy of aripiprazole augmentation in 30 treatment-resistant unipolar depression patients who had failed multiple previous antidepressant trials and had also failed augmentation with at least one other atypical neuroleptic. Prospective Global Assessment of Functioning and Clinical Global Impressions-Improvement scores were completed on each patient throughout treatment.RESULTS: Utilizing an intent-to-treat analysis (including 9 patients who dropped out prior to completion of 6 weeks), 46.7% (14/30) patients were rated much improved or very much improved with treatment. This improvement negatively correlated with Thase-Rush staging of treatment resistance. GAF scores also showed a significant improvement. Six of the 14 patients who initially improved subsequently relapsed (yielding a long-term net response rate of 26.7%).CONCLUSION: Aripiprazole may be effective as an antidepressant augmentation agent in highly treatment resistant patients who had failed a prior trial of another atypical neuroleptic.